Ideaya Biosciences Inc (IDYA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $38.41 (-0.52%), Market cap $2.53B, 52-week low–high $17.31 ~ $37.86.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydr
Financial statements, price targets, institutional (13F) holdings and related news for Ideaya Biosciences Inc are updated in real time on BlackAll Trade.
Ideaya Biosciences Inc trades at $38.41 (-0.52%). Real-time quotes and charts are available on BlackAll Trade.
Ideaya Biosciences Inc has a market cap of about $2.53B.
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Da